Last updated

Clinical data
Trade names Navane
Other namesThiothixene (USAN US)
AHFS/Drugs.com Monograph
MedlinePlus a682867
  • AU:B1
Routes of
By mouth
Drug class Typical antipsychotic
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances) [1]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability ~100%
Metabolism Hepatic
Elimination half-life 10–20 hours
Excretion Gastrointernal tract, faeces
  • (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard 100.233.356 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C23H29N3O2S2
Molar mass 443.62 g·mol−1
3D model (JSmol)
  • O=S(=O)(N(C)C)c2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN4CCN(C)CC4
  • InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8- Yes check.svgY

Tiotixene, or thiothixene is a typical antipsychotic agent currently sold under the brand name Navane which is predominantly utilised to treat acute and chronic schizophrenia. [2] Beyond its primary indication, it can exhibit a variety of effects common to neuroleptic drugs including anxiolytic, anti-depressive, and anti-aggressive properties. [3]


The drug was first synthesized and marketed in 1967 under the pharmaceutical company Pfizer. [2] [4] [5] [6] While the usage of the drug has declined in recent decades, the drug continues to be manufactured and prescribed in the US and Canada. [6]

Being a member of the thioxanthene class, it is chemically related to other typical neuroleptic agents such as chlorprothixene, clopenthixol, flupenthixol, and zuclopenthixol. Tiotixene also shares structural similarities with thioproperazine and pipotiazine, which are members of the phenothiazine class.

Medical uses

Tiotixene is a widely used drug for the treatment of various psychiatric disorders such as schizophrenia, bipolar disorder, mania, and behavioural disturbances. [7] The drug regulates behaviour and thoughts, and can also exhibit an anti-depressive effect. [3] [8]  

The side effect profile is similar to related antipsychotic agents, displaying weight gain, mental distress, and inability to sit still. Other possible symptoms include anticholinergic side effects such as insomnia, blurred vision, and dry mouth. [9] [10] Less frequently encountered side effects are drug-induced movement disorders such as Parkinson's syndrome and tardive dyskinesia. [11] [12]

The results of various dose-response studies (10–60 mg) indicate a stimulating effect at lower doses, which diminishes as higher doses are administered. [13] Overall, the efficacy of thiothixene when compared to other antipsychotic drugs was evaluated to be at least as effective regardless of the optimum dosage. [13] [14] [15]



As common with tricyclic psychotherapeutic agents, tiotixene is rapidly and extensively absorbed. [16] Peak serum concentration of the drug is achieved after 1–3 hours. [17] After absorption, the compound and its metabolites are spread widely throughout the body.  

The drug's metabolism proceeds rapidly and primarily in the liver. [2] [16] Although N-demethyltiotixene was identified as its major metabolite, the metabolic mechanisms remain elusive. [2] [18] After metabolism, most of the material is excreted through the faeces. [16]


Tiotixene [19]
SiteKi (nM)SpeciesRef
SERT Tooltip Serotonin transporter3,162–3,878Human [19] [20]
NET Tooltip Norepinephrine transporter30,200Human [19] [20]
DAT Tooltip Dopamine transporter3,630Human [19] [20]
5-HT1A 410–912Human [19] [21] [20]
5-HT1B 151Human [19]
5-HT1D 659Human [19]
5-HT1E >10,000Human [19]
5-HT2A 50–89Human [21] [20]
5-HT2C 1,350–1,400Human [21] [20]
5-HT3 1,860Human [19] [20]
5-HT5A 361Human [19]
5-HT6 208–320Human [19] [21] [20]
5-HT7 15.5Human [19] [21] [20]
α1 19ND [20]
   α1A 11–12Human [19] [21]
   α1B 35Human [19]
α2 95ND [20]
   α2A 80Human [19] [21]
   α2B 50Human [19] [21]
   α2C 52Human [19] [21]
β1 >10,000Human [19]
β2 >10,000Human [19]
D1 51–339Human [19] [20]
D2 0.03–1.4Human [19] [21] [22]
D3 0.3–186Human [22] [20]
D4 203–363Human [19] [20]
D4.2 410–685Human [22]
D5 261Human [19]
H1 4.0–12Human [19] [21] [23]
H2 411Human [19]
H3 1,336Guinea pig [19]
H4 >10,000Human [19]
mACh Tooltip Muscarinic acetylcholine receptor3,310ND [20]
   M1 ≥2,820Human [19] [20]
   M2 ≥2,450Human [19] [20]
   M3 ≥5,750Human [19] [21] [20]
   M4 >10,000Human [19]
   M5 5,376Human [19]
σ 1,780ND [20]
Values are Ki (nM). The smaller the value,
the more strongly the drug binds to the site.

Tiotixene shares its mechanism with related thioxanthenes which are all fundamentally used to control schizophrenia. Their mechanism of action involves the inhibition of different receptors, including 5-HT (serotonin), dopaminergic, histaminergic, and adrenergic receptors. [24] Blocking these receptors results in a reduction of synaptic levels of dopamine, serotonin, and other neurotransmitters that are involved with abnormal excitement in the brain during psychoses. [24] [25] This reduction of abnormal neurotransmission activity tends to alleviate the psychotic indications associated with schizophrenia. [26]

Tiotixene acts primarily as a highly potent antagonist of the dopamine D2 and D3 receptors (subnanomolar affinity). [19] It is also an antagonist of the histamine H1, α1-adrenergic, and serotonin 5-HT7 receptors (low nanomolar affinity), as well as of various other receptors to a much lesser extent (lower affinity). [19] It does not have any anticholinergic activity. [19] Antagonism of the D2 receptor is thought to be responsible for the antipsychotic effects of tiotixene.


Thiothixene has demonstrated toxicity in animal studies and isolated human tissue, displaying cytotoxic effects against various cell types. Observed toxic effects included growth inhibition of mouse fibroblasts, inhibition of protein synthesis by human glioma cells, and inhibition of leukocyte DNA synthesis. [27] [28]

Other compounds within the thioxanthene class have demonstrated hepatotoxicity in rodent experiments, and although anecdotal reports of thiothixene-induced liver failure exist, scientific data regarding the correlation lacks. [29] The absence of observational or longitudinal human studies on thiothixene in published literature precludes drawing conclusions regarding the significance of toxic effects at therapeutic dosages.


Thiothixene is a tricyclic compound consisting of a thioxanthene core with a (4-methylpiperazin-1-yl)propylidene side chain. [30] Several methods for the synthesis of thiothixene are described in literature, which all rely on varying thioxanthone derivatives upon which the (4-methylpiperazin-1-yl)propylidene side chain is constructed. [2] [16] [31]

Wyatt et al. described the synthesis of thiothixene via four different routes, three of which originated from the previous findings from Muren et al. One method described the synthesis of thiothixene by acetylation of 9-lithio-N,N-dimethylthioxanthene-2-sulfonamide. After acetylation, a condensation reaction, and an amine exchange the intermediate ketone was obtained. This intermediate was then converted into E- and Z-thiothixene through reduction with NaBH4, followed by dehydration using POCl3-pyridine. [2] [31]

Another method described by Muren et al. was performed using N,N-dimethylsulfamoyl-Z-thioxanthen-9-one as starting material. The introduction of the piperazinylpropylidene side chain was performed by a Wittig reaction. Following this, the methylation of the piperazinylpropylidene side chain was executed using various alkylating agents, yielding E- and Z-thiothixene. [31]  

The last method described by Wyatt et al, adapted from the study described by Muren and Bloom, used potassium benzenethiolate and 2-bromo-5-dimethylsulfamoylbenzoic acid as starting material. The resulting acid was treated with copper and PPA to form the thioxanthone intermediate. This ketone intermediate was then treated with the addition of the piperazinylpropylidene side chain and the loss of a water molecule to form Z- and E-Thiothixene. [2]  

The fourth method originating from D.C Hobbs involved condensing thiophenol with 2-chloro-5-dimethylsulfamoylbenzoic acid in an alkaline DMF solution at 130-140 °C. After a ring closure reaction with polyphosphoric acid at 70 °C, the ketone intermediate (N,N-dimethylsulfamoyl-Z-thioxanthen-9-one) was obtained. A wittig reaction was employed to connect the intermediate with the piperazinylpropylidene side chain, leading to the formation of both Z- and E-thiothixene isomers. [16] [32]

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay, together with mood stabilizers, in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Haloperidol</span> Typical antipsychotic medication

Haloperidol, sold under the brand name Haldol among others, is a typical antipsychotic medication. Haloperidol is used in the treatment of schizophrenia, tics in Tourette syndrome, mania in bipolar disorder, delirium, agitation, acute psychosis, and hallucinations from alcohol withdrawal. It may be used by mouth or injection into a muscle or a vein. Haloperidol typically works within 30 to 60 minutes. A long-acting formulation may be used as an injection every four weeks by people with schizophrenia or related illnesses, who either forget or refuse to take the medication by mouth.

<span class="mw-page-title-main">Atypical antipsychotic</span> Class of pharmaceutical drugs

The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), are a group of antipsychotic drugs largely introduced after the 1970s and used to treat psychiatric conditions. Some atypical antipsychotics have received regulatory approval for schizophrenia, bipolar disorder, irritability in autism, and as an adjunct in major depressive disorder.

<span class="mw-page-title-main">Risperidone</span> Antipsychotic medication

Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It is taken either by mouth or by injection. The injectable versions are long-acting and last for 2–4 weeks.

<span class="mw-page-title-main">Ziprasidone</span> Antipsychotic medication

Ziprasidone, sold under the brand name Geodon among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder. It may be used by mouth and by injection into a muscle (IM). The IM form may be used for acute agitation in people with schizophrenia.

<span class="mw-page-title-main">Olanzapine</span> Atypical antipsychotic medication

Olanzapine, sold under the brand name Zyprexa among others, is an atypical antipsychotic primarily used to treat schizophrenia and bipolar disorder. For schizophrenia, it can be used for both new-onset disease and long-term maintenance. It is taken by mouth or by injection into a muscle.

<span class="mw-page-title-main">Aripiprazole</span> Atypical antipsychotic

Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. It is primarily used in the treatment of schizophrenia and bipolar disorder; other uses include as an add-on treatment in major depressive disorder and obsessive compulsive disorder (OCD), tic disorders, and irritability associated with autism. Aripiprazole is taken by mouth or via injection into a muscle. A Cochrane review found low-quality evidence of effectiveness in treating schizophrenia.

<span class="mw-page-title-main">Azapirone</span> Drug class of psycotropic drugs

Azapirones are a class of drugs used as anxiolytics, antidepressants, and antipsychotics. They are commonly used as add-ons to other antidepressants, such as selective serotonin reuptake inhibitors (SSRIs).

<span class="mw-page-title-main">Amoxapine</span> Tricyclic antidepressant medication

Amoxapine, sold under the brand name Asendin among others, is a tricyclic antidepressant (TCA). It is the N-demethylated metabolite of loxapine. Amoxapine first received marketing approval in the United States in 1980, approximately 10 to 20 years after most of the other TCAs were introduced in the United States.

<span class="mw-page-title-main">Dopamine antagonist</span> Drug which blocks dopamine receptors

A dopamine antagonist, also known as an anti-dopaminergic and a dopamine receptor antagonist (DRA), is a type of drug which blocks dopamine receptors by receptor antagonism. Most antipsychotics are dopamine antagonists, and as such they have found use in treating schizophrenia, bipolar disorder, and stimulant psychosis. Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting.

<span class="mw-page-title-main">Chlorprothixene</span> Typical antipsychotic medication

Chlorprothixene, sold under the brand name Truxal among others, is a typical antipsychotic of the thioxanthene group.

<span class="mw-page-title-main">Amisulpride</span> Atypical antipsychotic and antiemetic medication

Amisulpride is an antiemetic and antipsychotic medication used at lower doses intravenously to prevent and treat postoperative nausea and vomiting; and at higher doses by mouth to treat schizophrenia and acute psychotic episodes. It is sold under the brand names Barhemsys and Solian, Socian, Deniban and others. At very low doses it is also used to treat dysthymia.

<span class="mw-page-title-main">Sulpiride</span> Atypical antipsychotic

Sulpiride, sold under the brand name Dogmatil among others, is an atypical antipsychotic medication of the benzamide class which is used mainly in the treatment of psychosis associated with schizophrenia and major depressive disorder, and sometimes used in low dosage to treat anxiety and mild depression. Sulpiride is commonly used in Asia, Central America, Europe, South Africa and South America. Levosulpiride is its purified levo-isomer and is sold in India for similar purpose. It is not approved in the United States, Canada, or Australia. The drug is chemically and clinically similar to amisulpride.

<span class="mw-page-title-main">Flupentixol</span> Typical antipsychotic drug of the thioxanthene class

Flupentixol (INN), also known as flupenthixol, marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen and flupentixol . Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK, Australia, Canada, Russian Federation, South Africa, New Zealand, Philippines, Iran, Germany, and various other countries.

<span class="mw-page-title-main">Melperone</span> Antipsychotic drug

Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. It first entered clinical use in 1960s.

<span class="mw-page-title-main">Perospirone</span> Atypical antipsychotic medication

Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.

<span class="mw-page-title-main">Lurasidone</span> Atypical antipsychotic medication

Lurasidone, sold under the brand name Latuda among others, is an antipsychotic medication used to treat schizophrenia and bipolar disorder. It is taken by mouth.

<span class="mw-page-title-main">Tiospirone</span> Atypical antipsychotic drug

Tiospirone (BMY-13,859), also sometimes called tiaspirone or tiosperone, is an atypical antipsychotic of the azapirone class. It was investigated as a treatment for schizophrenia in the late 1980s and was found to have an effectiveness equivalent to those of typical antipsychotics in clinical trials but without causing extrapyramidal side effects. However, development was halted and it was not marketed. Perospirone, another azapirone derivative with antipsychotic properties, was synthesized and assayed several years after tiospirone. It was found to be both more potent and more selective in comparison and was commercialized instead.

<span class="mw-page-title-main">Clocapramine</span> Antipsychotic medication

Clocapramine, also known as 3-chlorocarpipramine, is an atypical antipsychotic of the iminostilbene class which was introduced in Japan in 1974 by Yoshitomi for the treatment of schizophrenia. In addition to psychosis, clocapramine has also been used to augment antidepressants in the treatment of anxiety and panic.


  1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. 1 2 3 4 5 6 7 Wyatt DK, Grady LT (1990-01-01). "Thiothixene". In Florey K, Al-Badr AA, Forcier GA, Brittain HG (eds.). Analytical Profiles of Drug Substances. Vol. 18. Academic Press. pp. 527–565. doi:10.1016/s0099-5428(08)60680-2. ISBN   978-0-12-260818-6.
  3. 1 2 Mann JJ (2009-08-03). "Before Prozac: The troubled history of mood disorders in psychiatry". The Journal of Clinical Investigation. 119 (8): 2117. doi:10.1172/JCI40286. ISSN   0021-9738. PMC   2719946 .
  4. Poulsen MØ, Dastidar SG, Roy DS, Palchoudhuri S, Kristiansen JE, Fey SJ (December 2021). "A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome". Molecules. 27 (1): 196. doi: 10.3390/molecules27010196 . PMC   8746497 . PMID   35011432.
  5. William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia. Elsevier. pp. 3214–. ISBN   978-0-8155-1856-3.
  6. 1 2 Eslami Shahrbabaki M, Dehnavieh R, Vali L, Sharafkhani R, et al. (Cochrane Schizophrenia Group) (October 2018). "Chlorpromazine versus piperacetazine for schizophrenia". The Cochrane Database of Systematic Reviews. 10 (10): CD011709. doi:10.1002/14651858.CD012790. PMC   6483621 . PMID   30378678.
  7. Xin C, Lihong W, Qiuyuan L, Hongzhuo L (July 2014). "Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation". International Journal of Pharmaceutics. 469 (1): 23–30. doi:10.1016/j.ijpharm.2014.04.044. PMID   24751344.
  8. Robertson MM, Trimble MR (September 1982). "Major tranquillisers used as antidepressants. A review". Journal of Affective Disorders. 4 (3): 173–193. doi:10.1016/0165-0327(82)90002-7. PMID   6127357.
  9. Browne MW (January 1968). "Experiences with thiothixene". The British Journal of Psychiatry. 114 (506): 123. doi:10.1192/bjp.114.506.123. PMID   5636080.
  10. Sarai K, Okada M (February 1987). "Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study". Pharmacopsychiatry. 20 (1 Spec No): 38–46. doi:10.1055/s-2007-1017128. PMID   2883680. S2CID   20384816.
  11. Overall JE, Hollister LE, Shelton J, Kimbell I, Pennington V (January 1969). "Broad-spectrum screening of psychotherapeutic drugs: thiothixene as an antipsychotic and antidepressant". Clinical Pharmacology and Therapeutics. 10 (1): 36–43. doi:10.1002/cpt196910136. PMID   4884295. S2CID   23287102.
  12. Yesavage JA, Tanke ED, Sheikh JI (October 1987). "Tardive dyskinesia and steady-state serum levels of thiothixene". Archives of General Psychiatry. 44 (10): 913–915. doi:10.1001/archpsyc.1987.01800220085012. PMID   2889439.
  13. 1 2 Gardos G, Cole JO (August 1973). "The dual action of thiothixene". Archives of General Psychiatry. 29 (2): 222–225. doi:10.1001/archpsyc.1973.04200020056007. PMID   4741513.
  14. Gallant DM, Bishop MP, Shelton W (September 1966). "A preliminary evaluation of P-4657B: a thioxanthene derivative". The American Journal of Psychiatry. 123 (3): 345–346. doi:10.1176/ajp.123.3.345. PMID   5921658.
  15. Bishop MP, Fulmer TE, Gallant DM (November 1966). "Thiothixene versus trifluoperazine in newly-admitted schizophrenic patients". Current Therapeutic Research, Clinical and Experimental. 8 (11): 509–514. PMID   4962777.
  16. 1 2 3 4 5 Hobbs DC (January 1968). "Metabolism of thiothixene". Journal of Pharmaceutical Sciences. 57 (1): 105–111. doi:10.1002/jps.2600570121. PMID   5652108.
  17. Hobbs DC, Welch WM, Short MJ, Moody WA, Van der Velde CD (September 1974). "Pharmacokinetics of thiothixene in man". Clinical Pharmacology and Therapeutics. 16 (3): 473–478. doi:10.1002/cpt1974163part1473. PMID   4415039. S2CID   42200908.
  18. Guthrie SK, Hariharan M, Kumar AA, Bader G, Tandon R (June 1997). "The effect of paroxetine on thiothixene pharmacokinetics". Journal of Clinical Pharmacy and Therapeutics. 22 (3): 221–226. doi:10.1046/j.1365-2710.1997.95175951.x. hdl: 2027.42/72596 . PMID   9447478.
  19. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  20. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Silvestre JS, Prous J (June 2005). "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes". Methods and Findings in Experimental and Clinical Pharmacology. 27 (5): 289–304. doi:10.1358/mf.2005.27.5.908643. PMID   16082416.
  21. 1 2 3 4 5 6 7 8 9 10 11 12 Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. (March 2003). "H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs". Neuropsychopharmacology. 28 (3): 519–526. doi: 10.1038/sj.npp.1300027 . PMID   12629531.
  22. 1 2 3 Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. (December 2005). "Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist". The Journal of Pharmacology and Experimental Therapeutics. 315 (3): 1278–1287. doi:10.1124/jpet.105.092155. PMID   16135699. S2CID   2247093.
  23. Kanba S, Richelson E (June 1984). "Histamine H1 receptors in human brain labelled with [3H]doxepin". Brain Research. 304 (1): 1–7. doi:10.1016/0006-8993(84)90856-4. PMID   6146381. S2CID   45303586.
  24. 1 2 Gao S, Han L, Luo D, Xiao Z, Liu G, Zhang Y, et al. (June 2022). "Deep learning applications for the accurate identification of low-transcriptional activity drugs and their mechanism of actions". Pharmacological Research. 180: 106225. doi:10.1016/j.phrs.2022.106225. PMID   35452801. S2CID   248309731.
  25. Bangwal R, Bisht S, Saklani S, Garg S, Dhayani M (January 2020). "Psychotic Disorders, Definition, Sign and Symptoms, Antipsychotic Drugs, Mechanism of Action, Pharmacokinetics & Pharmacodynamics with Side Effects & Adverse Drug Reactions: Updated Systematic Review Article". Journal of Drug Delivery and Therapeutics. 10 (1): 163–172. doi:10.22270/jddt.v10i1.3865. ISSN   2250-1177.
  26. Patel KR, Cherian J, Gohil K, Atkinson D (September 2014). "Schizophrenia: overview and treatment options". P & T. 39 (9): 638–645. PMC   4159061 . PMID   25210417.
  27. J. B. Roerig Division (March 1968). "Thiothixene (Navane)". Clinical Pharmacology & Therapeutics. 9 (2): 282–284. doi:10.1002/cpt196892282. ISSN   0009-9236. S2CID   209106681.
  28. Munyon WH, Salo R, Briones DF (February 1987). "Cytotoxic effects of neuroleptic drugs". Psychopharmacology. 91 (2): 182–188. doi:10.1007/BF00217059. PMID   2883697. S2CID   20832854.
  29. Abernathy CO, Zimmerman HJ (November 1975). "The toxicity of thioxanthene neuroleptics to isolated rat liver cells". Proceedings of the Society for Experimental Biology and Medicine. 150 (2): 385–389. doi:10.3181/00379727-150-39041. PMID   1208553. S2CID   21403569.
  30. Noori Tahneh A, Bagheri Novir S, Balali E (November 2017). "Density functional theory study of structural and electronic properties of trans and cis structures of thiothixene as a nano-drug". Journal of Molecular Modeling. 23 (12): 356. doi:10.1007/s00894-017-3522-6. PMID   29177682. S2CID   27183246.
  31. 1 2 3 Muren JF, Bloom BM (January 1970). "Thioxanthene psychopharmacological agents. II. 9-(3-aminopropylidene)-N,N-dimethylthioxanthene-2-sulfonamides". Journal of Medicinal Chemistry. 13 (1): 17–23. doi:10.1021/jm00295a005. PMID   5412109.
  32. Rani A, Aslam M, Pandey G, Pant BN (May 2023). "A review on synthesis of FDA-approved antipsychotic drugs". Tetrahedron. 138: 133430. doi:10.1016/j.tet.2023.133430. ISSN   0040-4020. S2CID   258316664.